GlassScriptPhysician profile
Jose R Alvarez
NPI 1346203304
$8,367.49
in general payments reported to CMS, 2019-2025
36 companies · $1,405 in 2025
The $1,405 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,711 · 2020: $983 · 2021: $895 · 2022: $1,027 · 2023: $1,420 · 2024: $927 · 2025: $1,405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,518 · Education: $234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,518.47 |
| Education | $233.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,731.64 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $1,671.63 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $476.45 | 2019-2025 | Jascayd, Stiolto Respimat |
| Regeneron Healthcare Solutions, INC. | $320.07 | 2024-2025 | Dupixent |
| Boston Scientific Corporation | $292.38 | 2022-2024 | Eluvia, Watchman Access System, Ekosonic |
| Genzyme Corporation | $286.56 | 2021-2025 | |
| Grifols USA, LLC | $256.80 | 2019-2025 | Prolastin-C Liquid |
| Actelion Pharmaceuticals US, INC. | $255.72 | 2019-2024 | Uptravi, Opsumit |
| Mylan Specialty L.P. | $229.81 | 2019-2023 | Yupelri, Yupelri |
| Inari Medical, INC. | $193.35 | 2021 | |
| Inspire Medical Systems, INC. | $170.63 | 2025 | Inspire |
| Harmony Biosciences LLC | $162.19 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $159.61 | 2020-2025 | Acthar |
| Insmed, INC. | $158.39 | 2023-2025 | Arikayce |
| Mallinckrodt Enterprises LLC | $124.99 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $97.19 | 2023 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Verona Pharma, INC. | $77.18 | 2025 | Ohtuvayre |
| Paratek Pharmaceuticals, INC. | $70.44 | 2020-2024 | Nuzyra |
| Viatris Specialty LLC | $70.05 | 2025 | Yupelri |
| United Therapeutics Corporation | $65.35 | 2024-2025 | Orenitram, Remodulin, Orenitram |
| Sunovion Pharmaceuticals INC. | $64.73 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $59.56 | 2024 | Purified Cortrophin Gel |
| Jazz Pharmaceuticals INC. | $58.54 | 2019-2020 | |
| Lilly USA, LLC | $56.98 | 2025 | Zepbound |
| Inogen, INC. | $36.03 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Arbor Pharmaceuticals, INC. | $30.89 | 2019-2021 | |
| Circassia INC. | $30.23 | 2019 | |
| Merck Sharp & Dohme LLC | $27.11 | 2025 | Zerbaxa |
| Pfizer INC. | $21.83 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.63 | 2023 | Lifevest |
| Teva Pharmaceuticals USA, INC. | $21.61 | 2021 | |
| Resmed Corp | $20.35 | 2019 | |
| Optinose US, INC. | $17.06 | 2019 | |
| Nabriva Therapeutics, Plc | $15.53 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $14.98 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Alvarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.